“The positive results across all three Phase 3 TEMPO trials underscore the potential of tavapadon as a first-in-class D1/D5 ...

The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.

AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.

AbbVie (ABBV) announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose ...

Tavapadon hit the primary endpoint in one phase 3 trial in April, before AbbVie closed the takeover, and racked up another victory in September. AbbVie completed the set Monday by reporting data from ...

US pharma major AbbVie announced positive top-line results from its pivotal Phase III TEMPO-2 trial evaluating ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Tavapadon improved motor and daily living complications at week 26. The news comes nearly one month to the day after AbbVie ...

Treatment with tavapadon led to a statistically significant improvement in motor function compared with placebo. Topline results were announced from a phase 3 trial evaluating tavapadon, a selective ...

According to GlobalData, label expansions for the use of GLP-1R agonists in cardiovascular comorbidities may open up the possibility of partial reimbursement. Real-world data on GLP-1R agonists’ ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

Cerevel's pipeline behind emraclidine includes tavapadon, a dopamine D1/D5 partial agonist in phase 3 testing as a treatment for Parkinson’s disease, and darigabat, an α2/3/5-selective GABAA ...